PTI 808

Drug Profile

PTI 808

Alternative Names: PTI808

Latest Information Update: 11 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 04 Apr 2018 PTI 808 receives Fast Track designation for Cystic fibrosis [PO] (Combination therapy with PTI-428 and PTI-801) in USA
  • 01 Apr 2018 Preclinical trials in Cystic fibrosis (Combination therapy) in USA (PO) (Proteostasis Therapeutics Pipeline, April 2018)
  • 08 Jan 2018 Proteostasis Therapeutics plans a triple combination proof of concept trial combining PTI 428, PTI 801 and PTI 808 for Cystic fibrosis in first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top